MARKET

ZURA

ZURA

Zura Bio Limited
NASDAQ
4.270
-0.370
-7.97%
After Hours: 4.540 +0.27 +6.32% 17:55 04/30 EDT
OPEN
4.660
PREV CLOSE
4.640
HIGH
4.950
LOW
4.210
VOLUME
284.62K
TURNOVER
0
52 WEEK HIGH
14.00
52 WEEK LOW
2.000
MARKET CAP
186.15M
P/E (TTM)
-2.0390
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at ZURA last week (0422-0426)?
Weekly Report · 2d ago
12 Health Care Stocks Moving In Friday's Intraday Session
Biodexa Pharmaceuticals (NASDAQ:BDRX) stock rose 61.4% to $1.17 during Friday's regular session. The company's market cap stands at $4.4 billion. Zura Bio, Cullinan Therapeutics and Agenus were the biggest gainers during the session.
Benzinga · 4d ago
Mimedx Group, Cyclacel Pharmaceuticals, Predictive Oncology among healthcare movers
Healthcare On the Move: Mimedx Group, Cyclacel Pharmaceuticals, Predictive Oncology among healthcare movers. S&P 500 Health Care Sector -0.23% to 1637.36. Pharmaceuticals and Biotechnology & Life Science contributes 58% to index.
Seeking Alpha · 6d ago
Zura Bio Raises $112.5M Through Private Placement Deal
TipRanks · 04/23 10:13
Weekly Report: what happened at ZURA last week (0415-0419)?
Weekly Report · 04/22 11:43
Zura Bio Shares Rise 16% After Private Placement Valued at $112.5M
Zura Bio shares rose 16% Thursday after the company entered subscription agreements for a private placement. The private placement is expected to result in proceeds of $112.5 million. Shares of the biotechnology company are down 63% in the past 12 months. The company expects to use proceeds to support the accelerated development of tibulizumab.
Dow Jones · 04/18 17:16
Zura Bio stock jumps on plans to raise $112.5M in private financing
Seeking Alpha · 04/18 14:57
BRIEF-Zura Bio Announces Oversubscribed $112.5 Million Private Placement
Zura Bio Ltd announces Oversubscribed $112.5 million Private Placement. Company to sell 20.1 million Class A shares at $3.108 per share in the IPO. Company expects to use proceeds to fund operations through 2027. Zura Bio is a subsidiary of Zura Pharmaceuticals.
Reuters · 04/18 13:23
More
About ZURA
Zura Bio Limited is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab (ZB-106), ZB-168, and torudokimab (ZB-880) with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases, including systemic sclerosis and other novel indications with unmet needs. Tibulizumab (ZB-106) is an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of TALTZ (ixekizumab) and tabalumab that neutralizes IL-17A and BAFF. ZB-168 is a fully human, high affinity monoclonal antibody that binds and neutralizes the IL-7 receptor chain (IL-7R) alpha. Torudokimab (ZB-880) is a fully human, high affinity monoclonal antibody that neutralizes IL-33, preventing ST2-dependent and ST2-independent inflammation.

Webull offers Zura Bio Ltd stock information, including NASDAQ: ZURA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ZURA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ZURA stock methods without spending real money on the virtual paper trading platform.